Prophylaxis of oropharyngeal candidiasis with clotrimazole

E. Yeo, T. Alvarado, V. Fainstein, G. P. Bodey

Research output: Contribution to journalArticlepeer-review

55 Scopus citations


A total of 202 evaluable cancer patients were randomly assigned to receive or not receive oral clotrimazole as antifungal prophylaxis during hospitalization. Oropharyngeal candidiasis occurred in 1% of the former patients and 27% of the latter patients (P < .00001). Candida sp were cultured from the initial throat specimens of 53 control patients and 55 patients who received prophylaxis. Oropharyngeal candidiasis subsequently developed in 2% of the former patients and 38% of the latter patients (P = <.00001). Oral clotrimazole is an effective agent for prophylaxis of oropharyngeal candidiasis in susceptible cancer patients.

Original languageEnglish (US)
Pages (from-to)1668-1671
Number of pages4
JournalJournal of Clinical Oncology
Issue number12
StatePublished - 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Prophylaxis of oropharyngeal candidiasis with clotrimazole'. Together they form a unique fingerprint.

Cite this